Table 1.
CD47-targeted bsAbs in clinical trials as of March 2021 (44).
| bsAb | Sponsor | Format | Targets | Disease area | Development stages | ClinicalTrials.gov Identifier | Status | Preliminary Clinical Data Reported (Ref.) |
|---|---|---|---|---|---|---|---|---|
| IBI322 | Innovent Biologics (Suzhou) Co. Ltd. | Not available | CD47/PD-L1 | Solid tumors and hematological tumors | Phase I | NCT04338659 | Not yet Recruiting | No |
| Phase I | NCT04328831 | Recruiting | Yes (25, 46) | |||||
| HX009 | Waterstone Hanxbio Pty Ltd | Antibody-receptor fusion | PD-1/CD47 | Malignancies (liver cancer, stomach cancer, and colorectal cancer and so on) | Phase I | NCT04097769 | Recruiting | No |
| IMM0306 | ImmuneOnco | Antibody-receptor fusion | CD47/CD20 | B-cell Non-Hodgkin’s Lymphoma | Phase I | NCT04746131 | Not yet Recruiting | No |
| TG-1801 | NovImmune, TG Therapeutics | Antibody-receptor fusion | CD47/CD19 | Haematologicalmalignancies (B cell lymphoma) | Phase I | NCT03804996 | Recruiting | No |
| SL-172154 | Shattuck Labs, Inc | Antibody-receptor fusion | SIRPα-Fc-CD40L | Ovarian Cancer | Phase I | NCT04406623 | Recruiting | Yes (47) |